Evaluation of the Siemens VERSANT® CT/GC DNA 1.0 Assay (kPCR) for detection of Chlamydia trachomatis and Neisseria gonorrhoeae

The Siemens VERSANT kPCR system is an automated system which combines extraction of nucleic acids from 96 samples with subsequent real-time PCR. The VERSANT CT/GC DNA 1.0 (kPCR) assay detects Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) in a multiplex real-time PCR on this system. We co...

Full description

Saved in:
Bibliographic Details
Published inJournal of microbiological methods Vol. 87; no. 2; pp. 139 - 142
Main Authors Bongaerts, Maarten, van de Bovenkamp, Jeroen H.B., Morré, Servaas A., Manders, Monique E.L.M., Heddema, Edou R.
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 01.11.2011
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The Siemens VERSANT kPCR system is an automated system which combines extraction of nucleic acids from 96 samples with subsequent real-time PCR. The VERSANT CT/GC DNA 1.0 (kPCR) assay detects Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) in a multiplex real-time PCR on this system. We compared this assay with the BD ProbeTe™ ET System (PT) and the Roche Cobas Amplicor (CA). Three different sets of samples were tested in the kPCR: PT pre-treated samples, prospectively collected urine samples during routine CT/GC testing and urine samples obtained in a blinded fashion by an external lab facility. Agreement of kPCR with the comparator tests was >0.99 for sample set I and complete agreement was observed for sample set II and III. The kPCR assay demonstrated to be an easy to use robust diagnostic platform. A few modifications to the manufacturer's instructions are recommended to intercept false positivity. We advise to retest samples with Cq values above 35cycles at least one time and we suggest checking the amplification curves. ► We evaluated the VERSANT CT/GC DNA 1.0 (kPCR) assay. ► The assay detects Chlamydia trachomatis and Neisseria gonorrhoeae. ► The assay was compared with BD Probetec and Roche Cobas Amplicor. ► Almost complete agreement was observed. ► The assay demonstrated to be an easy to use robust diagnostic platform. ► We suggest a few modifications to the manufacturer's instructions to intercept false positivity.
Bibliography:http://dx.doi.org/10.1016/j.mimet.2011.09.001
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0167-7012
1872-8359
DOI:10.1016/j.mimet.2011.09.001